espanolLa investigacion describe el perfil neuropsicologico de un paciente con esquizofrenia en Cucuta, Colombia. Se utilizo un diseno de investigacion tipo ensayo clinico con fin diagnostico y alcance descriptivo basado en un paciente de 52 anos diagnosticado con esquizofrenia paranoide desde los 17 anos, quien actualmente es tratado con antipsicotico atipico (risperidona 4,5 mg/dia) y antidepresivo triciclico (clorimipramina 300 mg/dia). Se evaluo mediante un protocolo neuropsicologico conformado por Evaluacion Cognitiva Montreal (MOCA, del acronimo en ingles Montreal Cognitive Assessment), Test del Trazo (Trail Making, en ingles) A y B, subpruebas del Test Barcelona, curva de aprendizaje del Test Verbal de California, Figura Compleja de Rey–Osterrieth, y subpruebas de WAIS III, cuyas respuestas generaron indicadores globales asociados con deterioro cognitivo leve, compromiso de la capacidad de atencion alternante, memoria de trabajo, conversion acustico-fonologica y memoria declarativa de largo plazo, al igual que sus funciones ejecutivas. EnglishThis research aims to describe the neuropsychological profile in a patient with schizophrenia in the city of Cucuta, Colombia. A clinical trial type research design with a diagnostic purpose and descriptive scope was used in a patient aged 52 diagnosed with paranoid schizophrenia since age 17, currently being treated with atypical antipsychotic (Risperidone 4.5 mg/day) and tricyclic antidepressants (Clomipramine 300 mg/day). A neuropsychological protocol consisting of Montreal Cognitive Assessment (MOCA), Trail Making Test A and B, subtest of Barcelona Test, learning curve of the California Verbal Learning Test, Rey–Osterrieth Complex Figure Test, and WAIS III subtests, recorded global indicators associated with mild cognitive impairment, commitment in the capacity of alternating attention, working memory, acoustic-phonemic conversion, and long-term declarative memory, as well as his executive functions.